European Geriatric Medicine - Supplement 1 - Volume 7 - October 2016

178 / 290

serotypes continue to emerge among over 90 pneumococcal
serotypes. As part of an ongoing surveillance program, the literature
was reviewed to inform recent changes in serotype distribution.
Methods: A review of Medline, EMBASE, Ingenta, Cochrane reviews,
CDC, WHO, and recent meetings was performed from March 2014 to
March 2015, using the terms serotype, serogroup, pneumococc*,
streptococcus pneumoniae; serotype distribution data for adult
invasive pneumococcal disease (IPD) and non-invasive pneumonia
were extracted and summarized, by region.
Results: Serotype data were available in 34 articles/presentations
covering varying time periods beyond 2010, mostly from areas where
pediatric PCV was part of the immunization program. Globally,
serotypes 3, 19A, 1 and 7F were the most prevalent PCV-serotypes
whereas 22F, 8 and 12F were the most common non-PCV serotypes.
Non-PCV13 serotypes with the highest prevalence in adults were as
follows, by region: In Europe, 12F, 22F, 8 and 9N; in North America,
22F, 23A, 6C and 12F in those with IPD; in Asia-Pacific, 34, 35B, 15A/F
and 22F; in Latin America, 12F, 8, 22F and 11A; and in Africa-East
Mediterranean, 12F, 15A, 8 and 16F. Serotype distribution tended to be
similar for IPD and non-invasive pneumonia.
Conclusions: A few years after PCV adoption in various countries,
several PCV- and non-PCV serotypes remain a significant source of
burden among adults.
P-542
Descriptive study of elderly HIV-infected patients in Loire Valley
area in France
C. Bernaud, C. Allavena, S. Pineau, C. Michau, P. Perre, P. Fialaire,
R. Vatan, A.L. Ruellan, F. Delamarre Damier, F. Raffi, H. Hitoto. France
Introduction: New antiretroviral drugs have helped to improve
quality of life and reduce mortality. HIV patients are ageing, with
more and more comorbidities, yet few epidemiological, clinical and
therapeutic studies are available.
Method: This descriptive study of HIV patients over 75, was conduc-
ted in six hospitals of the Loire Valley. Clinical and biological data,
were collected via an electronic medical record software (Nadis®);
Simplified geriatric assessment was conducted during a HIV routine
visit to assess their frailty.
Results: Among the 3,965 patients followed in the Loire Valley centers,
65 (1.6%) were aged over 75. 51 patients were included in the study
between January and May 2016 with a median age of 78.7 years, 74.5%
were men and 98% lived at home. The median follow-up of HIV
infection was 18, 8 years, median CD4 nadir was 181 cells/mm 3. At the
last visit all patients were on antiretroviral therapy and 98% had an
undetectable viral load (<50 copies/mL). Results of the simplified
geriatric assessment showed that 21.6% of the patients appeared in the
process of fragility, 3.9% as fragile. 60.8% of them had cognitive
disorders, 35.3% had depression, 25.5% had an undernutrition status,
45.9% had an insufficient vitamin D level. The median number of
therapeutic lines was 6.
Conclusion: oldHIV patients arewell managed and controlled for their
HIV infection but the prevalence of geriatric syndroms is important
andmakes themvulnerable. Coordinatedmanagement of HIV infection
and Geriatric approach is the key to support these patients.
P-543
Efficacy and immunogenicity of an investigational subunit
adjuvanted herpes zoster vaccine in older adults in Europe: results
from the ZOE-50 and ZOE-70 efficacy studies
J. Diez-Domingo1, M. Kovac 2, T. Vesikari3, R. Chlibek4, H. Lal5,*,
J.E. McElhaney6, A.L. Cunningham7, E. Athan8, J. Berglund9,
H.J. Downey 10, W. Ghesquière11, O. Godeaux5, **, I. Gorfinkel12,
S.-J. Hwang13, T. Korhonen3, M.J. Levin14, S. McNeil15, K. Pauksens16,
J. Puig-Barberà 1, T.J. Avelino-Silva17, A. Volpi18, D. Watanabe19, W. Yeo 20,
L. Campora 2, T. Zahaf 2, L. Oostvogels2, T.C. Heineman5,***. 1Vaccine
Research Unit, Fundación para el Fomento de la Investigación Sanitaria y
Biomédica (FISABIO), Valencia, Spain; 2GSK Vaccines, Wavre, Belgium;
3Vaccine Research Centre, University of Tampere, Finland; 4Faculty of
Military Health Sciences, University of Defence, Hradec Kralove, Czech
Republic; 5GSK Vaccines, King of Prussia, PA, USA; 6Health Sciences North
Research Institute, Sudbury, ON, Canada;7Westmead Institute for Medical
Research, Westmead, University of Sydney, Sydney, NSW, 8Department of
Infectious Disease, Barwon Health, Deakin University, Geelong, VIC,
Australia; 9Blekinge Institute of Technology and Blekinge Center for
Competence, Karlskrona, Sweden; 10Jacksonville Center for Clinical
Research, Jacksonville, FL, USA;11Section of Infectious Diseases, University
of British Colombia, Victoria, BC,12PrimeHealth Clinical Research, Toronto,
ON, Canada; 13Department of Family Medicine, Taipei Veterans General
Hospital, National Yang Ming University School of Medicine, Taipei,
Taiwan; 14Departments of Pediatrics and Medicine, University of Colorado
Anschutz Medical Campus, Aurora, CO, USA; 15Canadian Center for
Vaccinology, IWK Health Center and Nova Scotia Health Authority,
Dalhousie University, Halifax, NS, Canada; 16Department of Infectious
Diseases, Akademiska sjukhuset Uppsala University Hospital, Uppsala,
Sweden; 17Division of Geriatrics, University of Sao Paulo Medical School,
Sao Paulo, Brazil; 18Dipartimento di scienze cliniche, University of Rome
Tor Vergata, Rome, Italy; 19Department of Dermatology, Aichi Medical
University, Nagakute, Aichi, Japan; 20Illawarra Health and Medical
Research Institute, Graduate School of Medicine, University of
Wollongong, NSW, Australia
Current affiliations: *Pfizer, Collegeville, PA, USA; **Crucell Holland B.V.,
The Netherlands; ***Genocea Biosciences, Cambridge, MA, USA
Introduction: The recombinant herpes-zoster (HZ) subunit vaccine
candidate (HZ/su) has shown ≥90% efficacy (VE) against HZ and a
clinically acceptable safety profile in older adults in two phase 3
clinical trials (ZOE-50, ZOE-70 [NCT01165177, NCT01165229]). Herewe
report VE and immunogenicity results from these studies from
European countries.
Methods: Subjects were randomized 1:1 to receive 2 intramuscular
doses of HZ/su or placebo 2 months apart. We assessed VE in subjects
≥50 (ZOE-50) and ≥70 years of age (YOA) (pooled analysis from ZOE-
50 and ZOE-70) who received 2 vaccine doses and had no confirmed
HZ case within 1 month post-dose 2; humoral immune responses
(anti-glycoprotein E [gE] ELISA) in a subset of subjects ≥50YOA
from the pooled population; and cell-mediated immune responses
(gE-specific CD42+ T-cell frequency) in a subset of subjects ≥50YOA
from ZOE-50.
Results: 7,889 (ZOE-50) and 15,400 (pooled population) subjects
≥50YOA in Europe were vaccinated. VEs against HZ were 97.2% (95%
confidence interval [CI]: 91.4–99.5) in adults ≥50YOA and 90.1% (95%
CI: 82.0–95.1) in those ≥ 70YOA. One month post-dose 2, anti-gE
geometric mean concentrations in adults ≥ 50YOAwere 49,244 for HZ/
su and 1,260 mIU/mL for placebo (38.0- and 1.0-fold above baseline,
respectively). Vaccine response rates (VRRs) were 97.5% (HZ/su) and
2.7% (placebo). Median CD42+ T-cell frequencies were 1,599 (HZ/su)
and 109 events/106 CD42+ T-cells (placebo) (21.2- and 1.5-fold above
baseline, respectively). Respective VRRs were 94.2% and 0.0%.
Key conclusions: HZ/su vaccine is highly efficacious against HZ and
immunogenic in older adults in Europe.
Funding:GlaxoSmithKline Biologicals SA.
P-544
Evaluation of influenza virus A in elderly hospitalized
N.F. González1, C.R. Otero1, A.A. Sastre1, M.A. Cambra1, J.P. Torres1, B.A.
C. Veloz1. 1Geriatrics Service of the University Hospital of Getafe, Madrid,
Spain
Introduction: The influenza virus A is an entity related mainly with
febrile illness and respiratory symptoms. It is associated with high
morbidityandmortalityespeciallyamonghigh-riskgroups as isthecase
of our patients. The objective of our study is to analyze the complica-
tions and mortality associated with this entity in elderly patients.
Methods: Retrospective study with a sample of 44 positive results for
influenza patients admitted to the University Hospital of Getafe from
2009 to 2015 over 75 years.
Poster presentations / European Geriatric Medicine 7S1 (2016) S29–S259 S172